Relationship between glucose transporter, hexokinase and FDG-PET in esophageal cancer

Hepato-Gastroenterology

Volumn 52, Issue 62, 2005, Pages 486-490

  Tohma, Takayuki ^a   Okazumi, Shinichi ^a   Makino, Harufumi ^a   Cho, Akihiro ^a   Mochiduki, Ryoyu ^a   Shuto, Kiyohiko ^a   Kudo, Hidehiro ^a   Matsubara, Katsuhiko ^a   Gunji, Hisashi ^a   Ochiai, Takenori ^a  

^a CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Esophageal squamous cell carcinoma; FDG PET; Glucose transporter 1; Type II hexokinase

Indexed keywords

FLUORODEOXYGLUCOSE F 18; GLUCOSE TRANSPORTER; GLUCOSE TRANSPORTER 1; HEXOKINASE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG UPTAKE; ENZYME ACTIVITY; ESOPHAGUS CANCER; FEMALE; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOACTIVITY; SCORING SYSTEM;

ADULT; AGED; ESOPHAGEAL NEOPLASMS; FEMALE; FLUORODEOXYGLUCOSE F18; GLUCOSE TRANSPORTER TYPE 1; HEXOKINASE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MONOSACCHARIDE TRANSPORT PROTEINS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; STAINING AND LABELING;

EID: 20144389417     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Warburg O: On the origin of cancer cells. Science 1956; 123:309-314.
2. Pessin JE, Bell GI: Mammalian facultative glucose transporter family: structure and molecular regulation. Ann Rev Physiol 1992; 54:911-930.
3. Lerut T, Flamen P, Ectors N, et al: Histological validation of lymph node staging with FDG-PET scan in cancer of the esophagus and gastroesophageal junction. A prospective study based on primary surgery with extensive lymphadenectomy. Ann Surg 2000; 232:743-752.
4. Smith TAD: FDG uptake, tumor characteristics and response to therapy: a new review. Nucl Med Commun 1998; 19:97-105.
5. Okazumi S, Isono K, Enomoto K, et al: Evaluation of liver tumors using fluorine-18-fluorodeoxyglucose PET. Characterization of tumors and assessment of effect of treatment. J Nucl Med 1992; 33:333-339.
6. 18F-FDG in oncology. J Nucl Med Technol 2002; 30:3-9.
7. Fukunaga T, Okazumi S, Koide Y, Isono K, Imazeki K: Evaluation of esophageal cancers using fluorine-18-fluorodeoxyglucose PET. J Nucl Med 1998; 39:1002-1007.
8. Haber RS, Rathan A, Weiser KR, et al: GLUT1 glucose transporter expression in colorectal carcinoma. Cancer 1998; 83:34-40.
9. Brown RS, Wahl RL: Overexpression of Glut-1 glucose transporter in human breast cancer. Cancer 1993; 72:2979-2985.
10. Younes M, Juarez D, Lechago LV, Lerner SP: Glut 1 expression in transitional cell carcinoma of the urinary bladder is associated with poor patient survival. Anticancer Res 2001; 21:575-578.
11. Higashi T, Tamaki N, Honda T, et al: Expression of glucose transporters in human pancreatic tumors compared with increased FDG accumulation in PET study. J Nucl Med 1997; 38:1337-1344.
12. Younes M, Pathak M, Finnie D, et al: Expression of the neutral amino acids transporter ASCT1 in esophageal carcinomas. Anticancer Res 2000; 20:3775-3779.
13. Kato H, Takita J, Miyazaki T, et al: Glut-1 glucose transporter expression in esophageal squamous cell carcinoma is associated with tumor aggressiveness. Anticancer Res 2002; 22:2635-2640.
14. Kunkel M, Reichert TE, Benz P, et al: Overexpression of Glut-1 and increased glucose metabolism in tumors are associated with a poor prognosis with oral squamous cell carcinoma. Cancer 2003; 97:1015-1024.
15. Reske SR, Grillenberger KG, Glatting G, et al: Over-expression of glucose transporter 1 and increased FDG uptake in pancreatic carcinoma. J Nucl Med 1997; 38:1344-1348.
16. Higashi T, Tamaki N, Torizuka T, et al: FDG uptake, GLUT-1 glucose transporter and cellularity in human pancreatic tumors. J Nucl Med 1998; 39:1727-1735.
17. Avril R, Menzel M, Dose J, et al: Glucose metabolism of breast cancer assessed by 18F-FDG PET: histologic and immunohistochemical tissue analysis. J Nucl Med 2001; 42:9-16.
18. Brown RS, Leung JY, Kison PV, et al: Glucose transporter and FDG uptake in untreated primary human non-small cell lung cancer. J Nucl Med 1999; 40:556-565.
19. Kato H, Takita J, Miyazaki T, et al: Correlation of 18F- fluorodeoxyglucose (FDG) accumulation with glucose transporter (Glut-1) expression in esophageal squamous cell carcinoma. Anticancer Res 2003; 23:3263-3272.
20. 18F-FDG PET, and hexokinase-II and glucose transporter-1 expression in pancreatic cancer. J Nucl Med 2002; 43:173-180.
21. Fleir JS, Mueckler MM, Usher P, Lodish HF: Elevated levels of glucose transport and transporter messenger RNA are induced by ras or src oncogenes. Science 1987; 235:1492-1495.
22. Joost HG, Thorens B: The extended GLUT-family of sugar/polyol transport facilitators: Nomenclature, sequence characteristics, and potential function of its novel members. Mol Membr Biol 2001; 18:247-256.
23. Goel A, Mathupala SP, Pederson PL: Glucose metabolism in cancer. Evidence that demethylation events play a role in activating type II hexokinase gene expression. J Biol Chem 2003; 278:15333-15340.
24. Lee MG, Pederson PL: Glucose metabolism in cancer. Importance of transcription factor-DNA interactions within a short segment of the proximal region of the type II hexokinase promoter. J Biol Chem 2003; 278:41047-41058.